<DOC>
	<DOCNO>NCT02955004</DOCNO>
	<brief_summary>The purpose study study effect transthoracic electrical cardioversion restoration sinus rhythm patient present recent onset atrial fibrillation , regard new silent cerebral thrombo-embolic lesion cognitive function , well electrical functional/structural reverse remodelling , effect inflammatory change / specific cardiac biomarkers , vasoactive peptide , coagulation activity , active fibrinolysis .</brief_summary>
	<brief_title>Electrical Cardioversion Recent Onset Atrial Fibrillation - Silent Thromboembolic Events , Reverse Atrial Remodeling</brief_title>
	<detailed_description>Working plan This study give information incidence silent cerebral thrombo-embolic event patient recent onset AF , population expect consist mostly paroxysmal AF patient . Patients atrial fibrillation ( AF ) duration le 48 hour fulfil inclusion exclusion criterion include study cardiologist day cardioversion , study nurse notify plan investigation . The patient undergo clinical examination , clinical history take blood sample . Once 12 lead ECG , echocardiography , questionnaire , telemetry MR do patient electrically cardioverted After cardioversion patient subject echocardiography heart , blood-sampling , 12 lead ECG , MR brain . The patient discharge study echocardiography heart MR brain day 7 - 10 . Thereafter patient follow 30 day - see flowchart . The day cardioversion define Day 0 . 3.1 . ASSESSMENT OF REMODELING/REVERSE REMODELING 3.1.1 . Electrical remodel Standard 12-Lead electrocardiography ( ECG ) every health care visit . ( Day -1 , Day 0 immediately DCC , Day 0 discharge , Day 7-10 30 ) . Recorded automatic analysis interval , Paper speed 50 mm/sec . O Data collect : Rhythm , heart rate , P wave duration amplitude . 3.1.2 . Functional remodeling ( Echocardiographic analysis ) - App . 1 . Left right atrial dimension volumes 53 . Global leave atrial function , leave atrial ejection fraction : ( assess 2D speckle track ) 53 , 54 Left ventricular ejection fraction leave ventricular diastolic function ( transmitral velocity , E/E ' index ) 53-56 O Echocardiographic data collect stored routinely used database department Clinical Physiology raw image separate database dedicate study ( care investigator ) offline review measurement . The Core lab Uppsala analysis . O Time collection : prior cardioversion , within 24 h cardioversion day 7 - 10 cardioversion . 3.1.3.Neurohormonal - inflammatory index , cardiac biomarkers , vasoactive peptide . High-sensitivity cardiac troponin T ( hsTnT ) N-terminal pro-brain natriuretic peptide ( Nt-proBNP ) measure sensitive specific marker cardiac injury ⁄ strain ⁄ filling pressure B-type natriuretic peptide level correlate AF burden patient lone AF strong predictor recurrent arrhythmia ablation . ( A stable fragment vasoactive peptide , C-terminal -proendothelin-1 measure relation recurrence AF , may risk factor embolism possible role pathogenesis recurrence AF , association atrial dilatation , fibrosis , hypertrophy , may contribute AF persistence embolism ) C-Reactive protein ( CRP ) Interleukin-662-65 Routine blood test : ( Hb , Platelets , White blood cell count , Na , K , Creatinine , international normalize ratio ( INR ) , thyroid-stimulating hormone ( TSH ) , free-T4 ) : cardioversion . O Blood sample test : Day 0 ( sample 1 ) 4 + 1 hour cardioversion time MRI 2 discharge ( sample 2 ) day 7-10 ( sample 3 ) . The core lab Uppsala analysis . 3.2 . RHYTHM MONITORING O Continuous ECG monitoring O During cardioversion print cardioverter telemetry 7 - 10 day Holter . O 7-day Holter monitoring . To initiated Day 0 prior cardioversion 7 day . The Core lab Uppsala analysis . 12 lead ECG recording As symptom indicate recurrence AF . Data collect : Time first P-wave ass sinus node recovery DC time immediate recurrence AF . AF burden ( define total time AF first 7 day ) Time first AF recurrence ( sustained AF ; duration &gt; 30 second first 7 day , first symptom AF confirm ECG ) Number sustain non-sustained AF episode first 7 day Mean , median - range duration AF episodes first 7 Days 3.3 . ASSESSMENT OF THROMBOEMBOLIC BIOMARKERS , MENTAL TESTS AND CEREBRAL ISCHEMIC EVENTS 3.3.1 . Biomarkers Coagulation activity analyse plasma marker thrombin activity ( P-selectin , d-dimer , prothrombin fragment 1+2 , von Willebrand factor antigen ( vWF-Ag ) ) factor VIII : C. Active fibrinolysis ( plasmin-alpha 2-plasmin inhibitor complex : PIC ) P-fibrinogen och P-Fibrin Platelet activity ( platelet factor 4 : PF4 ) . Brain damage marker : S100 Blood sample test . 3.3.2 . Neurological / Cognitive assessment National Institute Health Stroke Scale ( NIHSS ) : Standardized assessment neurological deficit66 . To perform : Day 0 prior cardioversion , Day 7-10 , Day 30 clinically evident cerebrovascular event . Mini-Mental-Test ( Mini Mental State Examination , MMSE ) Trail Making Test A och B ( TMT A och B ) To perform : Day 0 prior cardioversion , Day 7-10 , Day 30 clinically evident cerebrovascular event . 3.3.3 . Brain magnetic resonance imaging . MRI perform assessment silent thromboembolism , define 2-3 mm large lesion restrict diffusion MRI diffusion weight sequence.51,71-75 Silent clinically evident cerebrovascular event occur cardioversion detect eventually count late come emboli relation reverse remodel . To perform : Prior within 24 hour DCC , Day 0 , Day 7 - 10 DCC . Data collect : presence , size , number , vascular distribution focal abnormality consistent embolic lesion . Technique MRI without contrast injection : Sag T2 T1 position obtain transversal slice high reproducibility . `` DWI '' transversal , 5 mm slice , b=0 och b=1000 , calculation `` ADC '' map , usually automatic scanner T2 tse/fse transversal , 5 mm slice T2 FLAIR transversal , 5 mm slice 4 . Statistical analysis , sample size , data handle This pilot study give information incidence silent cerebral thromboembolic event associate clinical variable may affect outcome , patient recent onset AF expect mainly suffer paroxysmal AF . Based previous report patient undergo MRI AF ablation , % patient chronic cerebral lesion detect MRI baseline varies widely 4 79 % , 10 % representative figure patient paroxysmal AF . Previous observation report vary frequency new silent cerebral lesion MRI AF ablation ( 4-38 % ) , coronary angiography ( 10 % ) retrograde aortic catheterisation patient aortic valve stenosis ( 22 % ) . New asymptomatic cerebral ischemic lesion patient undergo AF ablation report use irrigated radiofrequency ( RF ) catheter ( 7-11 % ) , common routine ablation procedure , even high frequency lesion ( 37 % ) use specialized circular RF ablation catheter . Based observation investigator argue 20 % increase incidence new asymptomatic cerebral ischemic lesion patient undergo DC cardioversion would clinically significant warrant alternative routine cardioversions . Determination sample size Considering 20 % increase ( i.e . 10 % baseline 30 % ) incidence silent cerebral lesion follow electrical cardioversion , require number patient reject null-hypothesis 90 % power 0.05 significance level ( two-sided ) 35 . To allow drop-outs , 40 patient include study . The sample size calculation perform software `` nQuery Advisor '' version 7.0 . It reasonable perform pilot study 40 patient , order get indication number silent cerebral event . A total 70 patient screened ensure 40 patient remain sinus rhythm least 7 day cardioversion . Categorical variable report count percentage , whereas continuous variable mean standard deviation ( SD ) medians interquartile range , applicable . The relationship clinical variable ( qualify history duration AF , AF duration , CHADS2VASC score , biomarkers , conversion sinus rhythm , leave atrial function leave atrial volume ) , confound variable incidence new silent cerebral ischemic lesion Day 1 7-10 post MR test multiple logistic regression model , use stepwise selection procedure ( p &lt; 0.05 ) . The model validate use bootstrapping . The number new silent cerebral ischemic lesion model poisson negative binomial regression model , applicable . Median concentration biomarkers compare baseline level nonparametric Wilcoxon rank-sum test Kruskal- Wallis test appropriate . The association biomarker concentration new embolic lesion evaluate follow period 7 -10 day . The association baseline concentration biomarker new embolic lesion assess univariable Cox proportional hazard model . Biomarkers model continuous variable ( express 1 SD increment ) linearity hazard test appropriate transformation use restrict cubic spline account possible nonlinear relationship . Cox multivariable model perform evaluate independent prognostic value biomarker separately ; adjust baseline covariates emerge statistically significant stepwise selection procedure ( p &lt; 0.05 ) . The investigator also investigate whether addition different combination biomarkers improve discrimination model . The independent prognostic value biomarker new embolic lesion assess univariable multivariable Cox model . Each biomarker measure baseline , Day 1 immediately DCC , discharge , 7 - 10 day , 1 month analyse graphically time patient level well summary statistic . All probability value two-tailed , 95 % confidence interval ( CIs ) calculate . Because exploratory nature study , adjustment multiplicity statistical analysis make . A 2-sided P-value &lt; 0.05 consider statistically significant . 5 . Clinical Significance It paramount importance assess electrical cardioversion perform within 48 hour AF onset , without precede oral anticoagulation , result silent stroke , present clinical routine scientific data available . A 20 % increase incidence new asymptomatic cerebral ischemic lesion patient undergo DC cardioversion study define clinically significant . If cardioversion strategy identify result 10 % low incidence event , figure may regard clinically significant .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Intracranial Embolism</mesh_term>
	<criteria>Atrial fibrillation recent onset ( le 48 hour ) ongoing time baseline MRI . Age : 1875 year 1 . Recent ( less 3 month ) cardioversion AF atrial flutter 2 . Previous clinical cerebrovascular event 3 . Congestive heart failure New York Heart Association ( NYHA ) function class III IV 4 . Previously document moderate severely decreased leave ventricular ejection fraction ( LVEF less 35 % ) 5 . Previously document marked mitral regurgitation stenosis 6 . Atrial flutter , atypical atrial flutter intraatrial reentry tachycardia 7 . Contraindications electrical cardioversion 8 . Permanent implant cardiac device ( event recorder accept ) 9 . Contraindication nuclear magnetic resonance imaging ( MRI ) see separate list addendum 1 . 10 . Known coagulation defect spontaneous INR activate partial thromboplastin time ( APTT ) level therapeutic level 11 . Current Vitamin K antagonist ( VKA ) Novel Oral Anticoagulation ( NOAC ) treatment 12 . Spontaneous conversion sinus rhythm prior first MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>silent brain embolism</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>cardioversion</keyword>
</DOC>